TuHURA Biosciences (HURA) Competitors $3.31 -0.41 (-11.02%) Closing price 04:00 PM EasternExtended Trading$3.40 +0.09 (+2.72%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock HURA vs. PHAR, DAWN, DNTH, IOVA, ABUS, AKBA, ZYBT, EOLS, XNCR, and ABCLShould you be buying TuHURA Biosciences stock or one of its competitors? The main competitors of TuHURA Biosciences include Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Akebia Therapeutics (AKBA), Zhengye Biotechnology (ZYBT), Evolus (EOLS), Xencor (XNCR), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. TuHURA Biosciences vs. Pharming Group Day One Biopharmaceuticals Dianthus Therapeutics Iovance Biotherapeutics Arbutus Biopharma Akebia Therapeutics Zhengye Biotechnology Evolus Xencor AbCellera Biologics TuHURA Biosciences (NASDAQ:HURA) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Do insiders & institutionals believe in HURA or PHAR? 0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer HURA or PHAR? In the previous week, TuHURA Biosciences had 11 more articles in the media than Pharming Group. MarketBeat recorded 11 mentions for TuHURA Biosciences and 0 mentions for Pharming Group. TuHURA Biosciences' average media sentiment score of 0.29 beat Pharming Group's score of -1.00 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Overall Sentiment TuHURA Biosciences Neutral Pharming Group Negative Does the MarketBeat Community believe in HURA or PHAR? Pharming Group received 18 more outperform votes than TuHURA Biosciences when rated by MarketBeat users. However, 100.00% of users gave TuHURA Biosciences an outperform vote while only 67.65% of users gave Pharming Group an outperform vote. CompanyUnderperformOutperformTuHURA BiosciencesOutperform Votes5100.00% Underperform VotesNo VotesPharming GroupOutperform Votes2367.65% Underperform Votes1132.35% Which has more risk and volatility, HURA or PHAR? TuHURA Biosciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Do analysts recommend HURA or PHAR? TuHURA Biosciences currently has a consensus price target of $12.67, indicating a potential upside of 282.68%. Pharming Group has a consensus price target of $30.00, indicating a potential upside of 185.99%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe TuHURA Biosciences is more favorable than Pharming Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, HURA or PHAR? TuHURA Biosciences has higher earnings, but lower revenue than Pharming Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$8.32MN/AN/APharming Group$320.71M2.23-$10.55M-$0.20-52.45 Is HURA or PHAR more profitable? TuHURA Biosciences has a net margin of 0.00% compared to Pharming Group's net margin of -6.09%. TuHURA Biosciences' return on equity of 0.00% beat Pharming Group's return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A N/A -152.88% Pharming Group -6.09%-7.65%-3.82% SummaryTuHURA Biosciences beats Pharming Group on 11 of the 15 factors compared between the two stocks. Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HURA vs. The Competition Export to ExcelMetricTuHURA BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$144.58M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / SalesN/A250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book-0.816.466.794.50Net Income-$8.32M$143.98M$3.23B$248.18M7 Day Performance-14.91%3.04%4.07%1.14%1 Month Performance-21.19%7.44%12.52%15.20%1 Year PerformanceN/A-2.46%16.83%6.56% TuHURA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HURATuHURA BiosciencesN/A$3.31-11.0%$12.67+282.7%N/A$144.58MN/A0.00N/ANews CoverageEarnings ReportAnalyst RevisionPHARPharming Group1.653 of 5 stars$9.81-2.2%$30.00+206.0%+11.5%$667.04M$297.20M-37.71280Negative NewsGap UpDAWNDay One Biopharmaceuticals2.9161 of 5 stars$6.58+2.0%$30.57+364.6%-58.8%$666.96M$161.92M-6.3960DNTHDianthus Therapeutics1.2877 of 5 stars$20.08+2.5%$54.33+170.6%-24.9%$645.09M$6.24M-8.0380IOVAIovance Biotherapeutics4.4379 of 5 stars$1.93+10.3%$14.80+666.8%-81.5%$644.49M$212.68M-1.30500Trending NewsGap DownHigh Trading VolumeABUSArbutus Biopharma1.8887 of 5 stars$3.35+3.7%$5.50+64.2%+4.6%$641.46M$6.17M-7.7990Earnings ReportGap UpAKBAAkebia Therapeutics4.2431 of 5 stars$2.43-4.7%$6.63+172.6%+153.9%$636.14M$160.18M-10.56430High Trading VolumeZYBTZhengye BiotechnologyN/A$13.43+30.3%N/AN/A$633.44M$189.75M0.00278Gap DownEOLSEvolus3.5838 of 5 stars$9.98+1.8%$23.75+138.0%-25.8%$631.87M$266.27M-10.97170Gap UpHigh Trading VolumeXNCRXencor3.7201 of 5 stars$8.77+5.3%$29.50+236.4%-65.7%$624.00M$110.49M-2.74280Gap UpABCLAbCellera Biologics2.752 of 5 stars$2.06+1.5%$7.50+264.1%-44.1%$614.75M$28.83M-3.38500 Related Companies and Tools Related Companies PHAR Competitors DAWN Competitors DNTH Competitors IOVA Competitors ABUS Competitors AKBA Competitors ZYBT Competitors EOLS Competitors XNCR Competitors ABCL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HURA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HURA Stock Free HURA Stock Alerts